keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy-induced nausea and vomiting

keyword
https://www.readbyqxmd.com/read/27919978/control-of-nausea-and-vomiting-in-patients-with-colorectal-cancer-receiving-chemotherapy-with-moderate-emetic-risk
#1
Akio Suzuki, Ryo Kobayashi, Hironori Fujii, Hirotoshi Iihara, Takao Takahashi, Kazuhiro Yoshida, Yoshinori Itoh
BACKGROUND: Chemotherapy with moderate emetic risk (MEC), including irinotecan-based and oxaliplatin-based chemotherapy regimens, are predominantly used for colorectal cancer chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) remain unsatisfactorily controlled. PATIENTS AND METHODS: The rates of prevalence of antiemetic medication and the control of CINV were investigated from medical records in patients with colorectal cancer who received the first cycle of irinotecan-based or oxaliplatin-based regimens...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27915445/granisetron-extended-release-injection-a-review-in-chemotherapy-induced-nausea-and-vomiting
#2
Emma D Deeks
An extended-release (ER) subcutaneously injectable formulation of the first-generation 5-HT3 receptor antagonist granisetron is now available in the USA (Sustol(®)), where it is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide combination chemotherapy regimens in adults. Granisetron ER is administered as a single subcutaneous injection and uses an erosion-controlled drug-delivery system to allow prolonged granisetron release...
December 3, 2016: Drugs
https://www.readbyqxmd.com/read/27914995/transdermal-skin-patch-based-on-reduced-graphene-oxide-a-new-approach-for-photothermal-triggered-permeation-of-ondansetron-across-porcine-skin
#3
Florina Teodorescu, Gurvan Quéniat, Catherine Foulon, Marie Lecoeur, Alexandre Barras, Samia Boulahneche, Mohmaed Salah Medjram, Thomas Hubert, Amar Abderrahmani, Rabah Boukherroub, Sabine Szunerits
The development of a skin-mounted patch capable of controlled transcutaneous delivery of therapeutics through thermal activation provides a unique solution for the controlled release of active principles over long-term periods. Here, we report on a flexible transdermal patch for photothermal triggered release of ondansetron (ODS), a commonly used drug for the treatment of chemotherapy-induced nausea and vomiting and used as model compound here. To achieve this, a dispersion of ODS-loaded reduced graphene oxide (rGO-ODS) nanosheets were deposited onto Kapton to produce a flexible polyimide-based patch...
November 30, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27909835/breakthrough-chemotherapy-induced-nausea-and-vomiting-report-of-a-nationwide-survey-by-the-cinv-study-group-of-japan
#4
Kazuo Tamura, Keisuke Aiba, Toshiaki Saeki, Yoichi Nakanishi, Toshiharu Kamura, Hideo Baba, Kazuhiro Yoshida, Nobuyuki Yamamoto, Yuko Kitagawa, Yoshihiko Maehara, Mototsugu Shimokawa, Koichi Hirata, Masaki Kitajima
BACKGROUND: We conducted a nationwide survey on chemotherapy-induced nausea and vomiting (CINV) in Japan and demonstrated good compliance with Japanese CINV guidelines, resulting in good control of vomiting. However, almost half the patients experienced breakthrough CINV. We analyzed the survey results in relationship to the management of patients with breakthrough CINV. METHODS: This multicenter, prospective, observational study analyzed data for 1910 patients in Japan scheduled for moderately or highly emetogenic chemotherapy (MEC and HEC, respectively)...
December 1, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27896642/seom-clinical-guideline-update-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-2016
#5
R de Las Peñas, A Blasco, J De Castro, Y Escobar, R García-Campelo, A Gúrpide, R Lopez-Lopez, M Majem, C A Rodríguez, J A Virizuela
Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27894202/rolapitant-for-the-prevention-of-delayed-nausea-and-vomiting-over-initial-and-repeat-courses-of-emetogenic-chemotherapy
#6
Bernardo Rapoport, Ronwyn van Eeden, Teresa Smit
Introduction Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. Although sustained antiemetic control across repeated chemotherapy cycles is important for cancer treatment continuation, few studies have investigated the efficacy of antiemetic prophylaxis over multiple chemotherapy cycles. Areas Covered Here we discuss the use of antiemetic hydroxytryptamine type 3 (5-HT3) receptor and neurokinin (NK)-1 receptor antagonists for prevention of CINV, limiting our review to clinical trials in the context of multiple-cycle chemotherapy, with a focus on the NK-1 receptor antagonist rolapitant...
November 29, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27889278/safety-and-efficacy-of-nepa-an-oral-fixed-combination-of-netupitant-and-palonosetron-in-older-patients
#7
Matti Aapro, Karin Jordan, Richard J Gralla, Giada Rizzi, Giorgia Rossi, Marco Palmas, Anna V Alyasova, Alla S Lisyanskaya, Snežana M Bošnjak, Paul J Hesketh
OBJECTIVES: Prevention of chemotherapy-induced nausea and vomiting is critical in older cancer patients. NEPA is an oral fixed combination of netupitant 300mg, a new NK1 receptor antagonist (RA), and palonosetron 0.5mg, a pharmacologically distinct 5-HT3 RA. This retrospective analysis evaluated the efficacy and safety of NEPA in older patients. METHODS: Patients aged ≥65 and ≥70years from one phase II and two phase III trials were considered. Chemotherapy-naive patients with malignant tumors were treated with anthracycline-cyclophosphamide (AC), non-AC-based moderately emetogenic chemotherapy (non-AC MEC), or highly emetogenic chemotherapy (HEC)...
November 23, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27885469/nepa-a-fixed-oral-combination-of-netupitant-and-palonosetron-improves-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-over-multiple-cycles-of-chemotherapy-results-of-a-randomized-double-blind-phase-3-trial-versus-oral-palonosetron
#8
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona-Huerta, Vincent Hansen, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Hope Rugo
PURPOSE: Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. NEPA showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with oral PALO in a single chemotherapy cycle; maintenance of efficacy/safety over continuing cycles is the objective of this study...
November 24, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27873176/palonosetron-aprepitant-and-dexamethasone-for-prevention-of-nausea-and-vomiting-after-high-dose-melphalan-in-autologous-transplantation-for-multiple-myeloma-a-phase-ii-study
#9
Atsushi Isoda, Rie Saito, Fuminori Komatsu, Yuki Negishi, Noriyasu Oosawa, Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, Akihiro Manaka
Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous stem cell transplantation (ASCT). We evaluated the efficacy and safety of a triple antiemetic combination of palonosetron, aprepitant, and low-dose dexamethasone in 24 MM patients who received melphalan conditioning (100 mg/m(2) on days 1-2) before ASCT (on day 4). Intravenous palonosetron (0.75 mg on day 1), oral aprepitant (125 mg on day 1; 80 mg on days 2-4), and intravenous dexamethasone (6...
November 21, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27868231/aprepitant-in-pediatric-patients-using-moderate-and-highly-emetogenic-protocols-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#10
Lucas Miyake Okumura, Fernanda D' Athayde Rodrigues, Maria Angelica Pires Ferreira, Leila Beltrami Moreira
AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study's selection and data extraction...
November 20, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27863614/guided-imagery-effects-on-chemotherapy-induced-nausea-and-vomiting-in-iranian-breast-cancer-patients
#11
Mahboobehsadat Hosseini, Batool Tirgari, Mansooreh Azizzadeh Forouzi, Yunes Jahani
BACKGROUND: The objective of this study was to examine the effect of guided imagery on chemotherapy induced nausea and vomiting in breast cancer patients. DESIGN: This was a quasi-experimental study in which a group of sample was evaluated pre and post intervention. A convenience sample of 55 eligible breast cancer patients enrolled to participate in this study after giving informed consent. They completed the Morrow Assessment of Nausea and Vomiting, before and after the intervention...
November 2016: Complementary Therapies in Clinical Practice
https://www.readbyqxmd.com/read/27829423/relationship-between-traditional-chinese-medicine-constitutional-types-with-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-an-observational-study
#12
Yi Liu, Ting Pan, Wenjing Zou, Ye Sun, Yun Cai, Rui Wang, Pingping Han, Zhe Zhang, Qunying He, Feng Ye
BACKGROUND: The theory of traditional Chinese medicine (TCM) constitution involves genetic characteristics, psychological factors, organ functions, and many other aspects. Studies have shown that TCM constitution is associated with HLA polymorphisms and has a genetic basis. A large number of Chinese studies have suggested that the clinical evolution of breast cancer may differ among patients with different TCM constitutions. In addition, patients with breast cancer and different TCM constitutions may have different degrees of myelosuppression after chemotherapy...
November 9, 2016: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/27826874/efficacy-and-safety-of-aprepitant-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-during-the-first-cycle-of-moderately-emetogenic-chemotherapy-in-korean-patients-with-a-broad-range-of-tumor-types
#13
Jeong Eun Kim, Joung-Soon Jang, Jae-Weon Kim, Yong Lee Sung, Chi-Heum Cho, Myung-Ah Lee, Do-Jin Kim, Myung-Ju Ahn, Kil Yeon Lee, Sun Jin Sym, Myong Choel Lim, Hun Jung, Eun Kim Cho, Kyung Wan Min
PURPOSE: This study evaluated the efficacy and safety of a 3-day aprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the first cycle of non-anthracycline plus cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) based on government guidelines in Korean patients. METHODS: This multicenter, randomized, double-blind, phase IV trial (NCT01636947) enrolled adult South Korean patients with a broad range of tumor types who were scheduled to receive a single dose of ≥1 MEC agent...
November 8, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27826686/resin-based-yttrium-90-microspheres-for-unresectable-and-failed-first-line-chemotherapy-intrahepatic-cholangiocarcinoma-preliminary-results
#14
Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M Sella, J Mark McKinney, Weiping Wang
PURPOSE: To evaluate the value of resin-based yttrium-90 ((90)Y) radioembolization for unresectable and failed first-line chemotherapy (cisplatin plus gemcitabine) intrahepatic cholangiocarcinoma (ICC). METHODS: From February 2006 to September 2015, a retrospective study was conducted of all patients who underwent resin-based (90)Y therapy for unresectable and failed first-line chemotherapy ICC. Tumor response was assessed using modified RECIST criteria; side effects were assessed using Common Terminology Criteria for Adverse Events version 4...
November 8, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27826027/evaluation-of-pentravan-%C3%A2-pentravan-%C3%A2-plus-phytobase-%C3%A2-lipovan-%C3%A2-and-pluronic-lecithin-organogel-for-the-transdermal-administration-of-antiemetic-drugs-to-treat-chemotherapy-induced-nausea-and-vomiting-at-the-hospital
#15
F Bourdon, M Lecoeur, L Leconte, V Ultré, M Kouach, P Odou, C Vaccher, C Foulon
The objective of this study was to evaluate five commercial ready-to-use transdermal vehicles (Phytobase(®), Lipovan(®), Pentravan(®), Pentravan(®) Plus and Pluronic Lecithin Organogel (PLO)), for the compounding of three antiemetic drugs (ondansetron, dexamethasone and aprepitant) and their administration in combination to treat chemotherapy-induced nausea and vomiting (CINV) at the hospital. Drugs were individually formulated in these vehicles and in mixture in Pentravan(®) Plus using different penetration enhancers...
November 5, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/27821979/comparison-of-efficacy-of-granisetron-and-promethazine-in-control-of-hyperemesis-gravidarum
#16
Ashraf Aleyasin, Elham Saffarieh, Hassan Torkamandi, Somayeh Hanafi, Fariborz Sadeghi, Atossa Mahdavi, Fatemeh Bahmaei, Mohammadreza Javadi
PURPOSE: Hyperemesis gravidarum is the third leading cause of hospitalization during pregnancy. 5-HT3-receptor antagonists are the most effective against chemotherapy-induced nausea and vomiting and radiation. This randomized study aimed to compare and evaluate the efficacies of granisetron and promethazine for controlling nausea and vomiting of pregnancy. METHODS: The included patients were administered (oral and intravenous) granisetron and promethazine randomly...
December 2016: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/27821107/acupuncture-with-different-acupoint-combinations-for-chemotherapy-induced-nausea-and-vomiting-study-protocol-for-a-randomized-controlled-trial
#17
Lili Gao, Bo Chen, Qiwen Zhang, Tianyi Zhao, Bo Li, Tao Sha, Jinxin Zou, Yongming Guo, Xingfang Pan, Yi Guo
BACKGROUND: Acupuncture is beneficial for controlling chemotherapy-induced nausea and vomiting (CINV). However, the effect of different acupoint combinations on controlling CINV remains unknown. This study aims to compare the effects of distal-proximal point association and local distribution point association on controlling CINV. METHODS/DESIGN: The study is a single-center, randomized controlled trial. A total of 240 participants will be randomly divided into four groups...
November 8, 2016: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/27816008/in-silico-investigation-into-the-interactions-between-murine-5-ht3-receptor-and-the-principle-active-compounds-of-ginger-zingiber-officinale
#18
Anna E Lohning, Wolfgang Marx, Liz Isenring
Gingerols and shogaols are the primary non-volatile actives within ginger (Zingiber officinale). These compounds have demonstrated in vitro to exert 5-HT3 receptor antagonism which could benefit chemotherapy-induced nausea and vomiting (CINV). The site and mechanism of action by which these compounds interact with the 5-HT3 receptor is not fully understood although research indicates they may bind to a currently unidentified allosteric binding site. Using in silico techniques, such as molecular docking and GRID analysis, we have characterized the recently available murine 5-HT3 receptor by identifying sites of strong interaction with particular functional groups at both the orthogonal (serotonin) site and a proposed allosteric binding site situated at the interface between the transmembrane region and the extracellular domain...
October 26, 2016: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/27815710/2016-updated-mascc-esmo-consensus-recommendations-prevention-of-nausea-and-vomiting-following-multiple-day-chemotherapy-high-dose-chemotherapy-and-breakthrough-nausea-and-vomiting
#19
Lawrence H Einhorn, Bernardo Rapoport, Rudolph M Navari, Jørn Herrstedt, Mary J Brames
PURPOSE: This review summarizes the recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting as agreed at the MASCC/ESMO Antiemetic Guidelines update meeting in Copenhagen in June 2015. METHODS: A systematic literature search using PubMed from January 01, 2009 through January 06, 2015 with a restriction to papers in English was conducted. RESULTS: There were three phase III randomized trials in patients undergoing high-dose chemotherapy and stem cell transplant and eight single arm non-randomized clinical studies (single in patients undergoing transplantation and one in patients receiving multiple-day chemotherapy treatment)...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27803457/an-analysis-of-behavioral-and-genetic-risk-factors-for-chemotherapy-induced-nausea-and-vomiting-in-japanese-subjects
#20
Naoki Mukoyama, Akira Yoshimi, Aya Goto, Haruka Kotani, Kazuhiro Ishikawa, Noriko Miyazaki, Masayuki Miyazaki, Kiyofumi Yamada, Fumitaka Kikkawa, Yoshinori Hasegawa, Norio Ozaki, Yukihiro Noda
There are individual differences in the frequency of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. We investigated the individual variability in susceptibility to CINV with focus on both behavioral factors and genetic factors in Japanese cancer patients. We performed a prospective study to investigate the association between patient attributes (backgrounds and habits as well as gene polymorphisms) and anorexia, nausea, or vomiting in 55 Japanese cancer patients undergoing chemotherapy at Nagoya University Hospital...
2016: Biological & Pharmaceutical Bulletin
keyword
keyword
98586
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"